CJ 30039Alternative Names: CJ-30039
Latest Information Update: 16 Jul 2016
$50 / €47 *
At a glance
- Originator CJ Cheiljedang Corp.
- Developer CJ HealthCare
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Undefined(In volunteers) in South Korea (PO)
- 30 Jun 2012 CJ Healthcare completes a phase I trial in healthy volunteers in South Korea (NCT01501435)
- 24 Dec 2011 Phase-I clinical trials in Undefined indication in South Korea (PO)